Premium
Making buprenorphine more accessible is goal of 3 bills: MAT, MATE and TREATS
Author(s) -
Knopf Alison
Publication year - 2021
Publication title -
alcoholism and drug abuse weekly
Language(s) - English
Resource type - Journals
eISSN - 1556-7591
pISSN - 1042-1394
DOI - 10.1002/adaw.33016
Subject(s) - buprenorphine , (+) naloxone , food and drug administration , opioid use disorder , opioid , narcotic antagonists , administration (probate law) , business , pharmacology , medicine , political science , law , receptor
More than two decades after the Food and Drug Administration's approval of buprenorphine‐naloxone as a treatment for opioid use disorder, Congress, which wasn't exactly enthusiastic back then, is now looking at three separate bills, all of which would loosen the regulations that made those bills possible.